Redhawk Wealth Advisors, Inc. Bristol Myers Squibb CO Transaction History

Redhawk Wealth Advisors, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$47.98 - $54.4 $334,708 - $379,494	6,976 New	6,976 $378,000
Q3 2023 Oct 13, 2023	SELL	$57.89 - $64.73 $3,936 - $4,401	-68 Reduced 0.57%	11,935 $692,000
Q2 2023 Jul 13, 2023	SELL	$63.71 - $70.74 $461,069 - $511,945	-7,237 Reduced 37.61%	12,003 $767,000
Q1 2023 Apr 28, 2023	BUY	$65.71 - $74.53 $232,941 - $264,208	3,545 Added 22.59%	19,240 $1.33 Million
Q4 2022 Feb 10, 2023	BUY	$68.48 - $81.09 $43,758 - $51,816	639 Added 4.24%	15,695 $1.13 Million
Q3 2022 Oct 27, 2022	BUY	$0.13 - $76.84 $468 - $276,854	3,603 Added 31.46%	15,056 $1.07 Million
Q2 2022 Aug 25, 2022	BUY	$72.62 - $79.98 $831,716 - $916,010	11,453 New	11,453 $882,000
Q2 2021 Aug 04, 2021	SELL	$61.91 - $67.42 $514,224 - $559,990	-8,306 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$59.34 - $66.74 $83,432 - $93,836	-1,406 Reduced 14.48%	8,306 $524,000
Q4 2020 Jan 26, 2021	SELL	$57.74 - $65.43 $159,766 - $181,044	-2,767 Reduced 22.17%	9,712 $602,000
Q3 2020 Nov 03, 2020	BUY	$57.43 - $63.64 $75,577 - $83,750	1,316 Added 11.79%	12,479 $752,000
Q2 2020 Jul 14, 2020	SELL	$54.82 - $64.09 $157,936 - $184,643	-2,881 Reduced 20.51%	11,163 $656,000
Q1 2020 Apr 14, 2020	BUY	$46.4 - $67.43 $195,900 - $284,689	4,222 Added 42.99%	14,044 $783,000
Q4 2019 Feb 25, 2020	BUY	$49.21 - $64.19 $483,340 - $630,474	9,822 New	9,822 $630,000
Q3 2019 Oct 04, 2019	SELL	$42.77 - $50.71 $63,085 - $74,797	-1,475 Closed	0 $0
Q2 2019 Aug 09, 2019	BUY	$44.62 - $49.34 $65,814 - $72,776	1,475 New	1,475 $67,000

2,425

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Redhawk Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Redhawk Wealth Advisors, Inc. with notifications on news.